Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats
Abstract
Background Cardiac arrest (CA) causes severe neurologic deficits and cognitive impairments. Empagliflozin is a newly developed antidiabetic drug and has been shown to reduce ischemia–reperfusion injury. This study aims to elucidate the neuroprotective effects of empagliflozin on global cerebral ischemic injury induced by CA in rats. Methods A total of 206 adult male Sprague–Dawley rats were subjected to a CA model via ventricular fibrillation and subsequent cardiopulmonary resuscitation. Animals were randomized into groups receiving either empagliflozin, β‐hydroxybutyrate (BHB), or vehicle post‐CA. Assessments included neurologic deficit scoring, histopathological evaluation, Fluoro‐Jade B staining, immunofluorescence staining, enzyme‐linked immunosorbent assay, Western blot analysis, and mitochondrial complex I activity. Results Treatment with empagliflozin led to a significant improvement in neurologic outcomes, as indicated by enhanced survival rates, higher neurologic deficit scores, and reduced neuronal damage in the hippocampal CA1 region. Empagliflozin administration was also associated with an upregulation of serum and cerebral BHB levels post CA. Furthermore, both empagliflozin and BHB treatment attenuated microglial activation and suppressed the release of proinflammatory cytokines TNF‐α (tumor necrosis factor alpha) and IL‐1β (interleukin‐1β) in both serum and brain tissue. Additionally, empagliflozin or BHB preserved the structural integrity of hippocampal…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.